Berlin – (January 30th, 2017)
The ProteomeTools consortium of TUM, JPT Peptide Technologies (JPT), SAP and Thermo Fisher Scientific announces the publication in Nature Methods of the chemical synthesis of more than 330,000 reference peptides (termed PROPEL for ProteomeTools Peptide Library) representing essentially all canonical proteins of the human proteome. Analysis of peptides by multi-modal liquid chromatography-tandem mass spectrometry (LC-MS/MS) created a compendium of millions of high quality reference spectra (termed PROSPEC for ProteomeTools Spectrum Compendium).
Reference peptides were assembled using JPT’s ultra high-throughput SpikeMix™ approach and resulting data enable verification of protein identifications from sparse observations and prediction of peptide behaviour in liquid chromatography and tandem mass spectrometry.
All data, representing eleven types of tandem mass spectrometry, are now freely accessible via the data analytics platform ProteomicsDB and the data repository PRIDE. They enable scientists to comprehensively study human proteomes and foster proteomics collaborations around the globe.
Within the project, we aim to generate another 1 Mio synthetic peptides and corresponding spectra with a focus on splice variants, cancer mutations and post-translational modifications such as phosphorylation, acetylation and ubiquitinylation. JPT will make all of these peptides commercially available and create the most comprehensive online peptide resource for mass-spectrometry-based proteomic assays.
"These results transform and exploit the draft map of the human proteome previously published in Nature into valuable new information and reagents." said Holger Wenschuh, CEO at JPT and added, "We are excited to see how cutting- edge peptide technologies, instrumentation and science come together to deliver meaningful data that uncover the dynamics of the human proteome".
JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG, is a DIN ISO 9001:2015 certified research and development partner and innovative service provider for peptide related projects in immunotherapy development, proteomics and drug discovery. JPT’s key technologies SPOT™ – for ultra-high-throughput peptide synthesis and screening, PepStar™ – for high-content peptide microarrays, PepTrack™ - for flexible peptide library assembly, PepMix™ – for antigen specific T-cell stimulation using peptide pools, and SpikeTide™/SpikeMix™ – for protein biomarker discovery and quantification accelerate research and development in areas such as cell and immunotherapy, vaccine development, biomarker discovery, peptide lead identification and optimization, and proteomics.
Technical University of Munich (TUM) is one of Europe’s leading research universities, with more than 500 professors, around 10,000 academic and non-academic staff, and 40,000 students. Its focus areas are the engineering sciences, natural sciences, life sciences and medicine, combined with economic and social sciences. TUM acts as an entrepreneurial university that promotes talents and creates value for society. In that it profits from having strong partners in science and industry. It is represented worldwide with a campus in Singapore as well as offices in Beijing, Brussels, Cairo, Mumbai, San Francisco, and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von Linde, and Rudolf Mößbauer have done research at TUM. In 2006 and 2012 it won recognition as a German "Excellence University." In international rankings, TUM regularly places among the best universities in Germany.
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com
JPT Peptide Technologies GmbH
Dr. Holger Wenschuh, CEO
12489 Berlin, Germany
T: +49 30 6392 5500
F: +49 30 6392 5501
JPT Peptide Technologies contributes a major milestone for human proteome analysis
Berlin – (January 30th, 2017)